DGAP-News: BB Biotech investiert Übernahme-Erlöse in neue Technologien – Dividende von CHF 3.05 vorgeschlagen

BB Biotech behauptete sich 2018 in einem herausfordernden Aktienmarktumfeld. Die Gesamtrendite fiel mit -5.2% in CHF (-2.2% in …
(Orginal – Story lesen…)

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
728